

Appendix A: Guideline Development Groups & Declarations of Interest

A.1 Guideline development group members

A.1.1 Guideline development group for 2015

Damien Longson (Guideline Chair)

Consultant Liaison Psychiatrist, Manchester Mental Health and Social Care Trust

Amanda Adler

Consultant Diabetologist, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust

Anne Bentley

Medicines Optimisation Lead Pharmacist, NHS East Lancashire Primary Care Trust

Christine Bundy (co-opted expert member)

Senior Lecturer in Behavioural Medicine, Institute for Inflammation & Repair, University of Manchester

Bernard Clarke (co-opted expert member)

Honorary Clinical Professor of Cardiology, Manchester Academic Health Science Centre, University of Manchester

Maria Cowell

Community Diabetes Specialist Nurse, Cambridge

Indranil Dasgupta (co-opted expert member)

Consultant Nephrologist, Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust

David Ronald Edwards (co-opted expert member)

Principal in General Practice, Whitehouse Surgery, Oxfordshire

Andrew Farmer

Professor in General Practice, Department of Primary Care Health Sciences, University of Oxford

Ian Lewin

Consultant Diabetologist, North Devon District Hospital, Northern Devon Healthcare NHS Trust

Natasha Jacques

Principal Pharmacist in Diabetes, Heart of England NHS Foundation Trust, Birmingham

Yvonne Johns

Patient/carer member

Natasha Marsland

Patient/carer member, Diabetes UK

Prunella Neale

Practice Nurse, Herschel Medical Centre, Berkshire

Jonathan Roddick

Principal General Practitioner, Woodseats Medical Centre, Sheffield

Mohammed Roshan (August 2012 - October 2013)

Principal in General Practice, Leicester City and County

Sailesh Sankar

Consultant Diabetologist, University Hospitals Coventry and Warwickshire NHS Trust

A.1.2 Guideline development group for 2009 (NICE clinical guideline 87)

Amanda Adler (Chair)

Consultant Physician with an interest in diabetes, Addenbrooke's Hospital, Cambridge

Claudette Allergyce

Principal Locality Pharmacist, Croydon Primary Care Trust

Tony Doherty

Diabetes Nurse Specialist and Service Improvement Officer, Diabetes UK (Scotland)

Andrew Farmer

University Lecturer in General Practice, University of Oxford

Niru Goenka

Consultant Physician with an interest in diabetes/endocrinology, Countess of Chester NHS Foundation Trust

Martin Hadley-Brown

General Practitioner, Thetford, Norfolk; Clinical Teacher at University of Cambridge Clinical School of Medicine

Philip Home

Professor of Diabetes Medicine and Consultant Physician in Diabetes and Metabolic Medicine, Newcastle Primary Care Trust

Philip Ivory

Patient/carer representative

Yvonne Johns

Patient/carer representative

Ian Lewin

Consultant Physician with an interest in diabetes/endocrinology, North Devon District Hospital

Alistair McGuire

Head of Social Policy, London School of Economics

Julie Wood

Diabetes Nurse Specialist, Diabetes and Renal Programme Manager, Kirklees Primary Care Trust

The following people were not full members of the GDG but were co-opted onto the group as expert advisers:

Anthony Barnett

Professor of Medicine, University of Birmingham and Heart of England NHS Foundation Trust

Andrew Krentz

Consultant in Diabetes and Endocrinology, Southampton University Hospitals
The following individual contributed expertise:

Alistair Gray

Director of the Health Economics Research Centre, Division of Public Health and Primary Care, University of Oxford

The Short Clinical Guidelines Technical Team was responsible for this guideline throughout its development. It was responsible for preparing information for the GDG, for drafting the guideline and for responding to consultation comments. The following people, who are employees of NICE, made up the technical team working on this guideline.

Tim Stokes

Associate Director

Beth Shaw

Technical Adviser

Francis Ruiz

Technical Adviser in Health Economics

Michael Heath

Project Manager

Lynda Ayiku

Information Specialist

A.1.3 Guideline development group for 2008 (NICE clinical guideline 66)

Professor Jonathan Mant (Chair)

Professor of Primary Care Stroke Research, University of Birmingham

Mrs Lina Bakhshi

Information Scientist, NCC-CC

Mrs Margaret Bannister

Nurse Consultant in Diabetes Care, Bradford and Airedale Primary Care Trust

Mrs Katherine Cullen

Health Economist, NCC-CC

Professor Melanie Davies

Professor of Diabetes Medicine, University of Leicester

Dr Jose Diaz

Health Services Research Fellow in Guideline Development, NCC-CC

Mrs Barbara Elster

Patient and Carer Representative, Essex

Dr Roger Gadsby

General Practitioner and Senior Lecturer in Primary Care, Warwickshire

Dr Anupam Garrib

Health Services Research Fellow, NCC-CC

Ms Irene Gummerson

Primary Care Pharmacist, Yorkshire

Dr Martin Hadley-Brown

General Practitioner Trainer, University of Cambridge

Professor Philip Home

Clinical Advisor to the GDG; Professor of Diabetes Medicine, Newcastle University

Mrs Kathryn Leivesley

Practice Nurse, North Manchester Primary Care Trust

Mrs Emma Marcus

Clinical Specialist Diabetes Dietitian, Hinckley and Bosworth Primary Care Trust

Mr Leo Nherera

Health Economist, National Collaborating Centre for Women's and Children's Health

Ms Roberta Richey

Health Services Research Fellow in Guideline Development, NCC-CC

Mr John Roberts

Patient and Carer Representative, Merseyside

Dr Mark Savage

Consultant Physician, North Manchester General Hospital

Lorraine Shaw

Paediatric Diabetes Clinical Nurse Specialist, Birmingham Children's Hospital

Dr Stuart Smelie

Consultant Chemical Pathologist, Bishop Auckland General Hospital

Ms Nicole Stack

Guideline Development Project Manager, NCC-CC

Ms Claire Turner

Guideline Development Senior Project Manager, NCC-CC

Ms Susan Varney

Health Services Research Fellow in Guideline Development, NCC-CC

Dr Jiten Vora

Consultant Physician Endocrinologist, Royal Liverpool and Broadgreen University Hospital

The following experts were invited to attend specific meetings and to advise the Guideline Development Group:

Dr Julian Barth

Consultant Chemical Pathologist, Leeds NHS Trust attended one meeting as a deputy for Dr Stuart Smellie

Dr Indranil Dasgupta

Consultant Physician and Nephrologist, Birmingham Heartlands Hospital

Dr Michael Feher

Consultant Physician, Chelsea Westminster Hospital attended one meeting as a deputy for Dr Mark Savage

Dr Charles Fox

Consultant Physician, Northampton General Trust attended one meeting as a deputy for Professor Melanie Davies

Natasha Jacques

Principal Pharmacist Medicine, Solihull Hospital attended one meeting as a deputy for Ms Irene Gummerson

Dr Eric Kilpatrick

Consultant Chemical Pathologist, University of Hull attended one meeting as a deputy for Dr Stuart Smellie

Dr Ian Lawrence

Consultant Diabetologist, University of Leicester attended one meeting as a deputy for Professor Melanie Davies and Dr Jiten Vora

Professor Sally Marshall

Professor of Diabetes, Newcastle University

Professor David Wood

Professor of Cardiovascular Medicine, Imperial College London

CG66 Acknowledgements

The Guideline Development Group (GDG) is grateful to Bernard Higgins, Jane Ingham, Rob Grant, Jill Parnham and Susan Tann of the NCC-CC for their support throughout the development of the guideline.

The GDG would like to thank the following individuals for giving their time to advise us regarding the design and interpretation of the economic model of analysis of third-line therapy with insulins, glitazones or exenatide in Type 2 diabetes:

- Professor Alastair Gray, University of Oxford
- Dr Philip Clarke, University of Sydney
- Dr Joanne Lord, National Institute for Health and Clinical Excellence.

The GDG would like to thank the following individuals for peer reviewing the guideline:

- Professor Simon Heller, University of Sheffield
- Professor David Owens, Llandough Hospital, Penarth
- Professor Bryan Williams, University of Leicester
- Dr Miles Fisher, Glasgow Royal Infirmary
- Professor Solomon Tesfaye, University of Sheffield
- Mr Irvine Turner, Patient Representative.

A.2 Declarations of interests

A.2.1 Declarations of interest for 2015

| GDG Member | Interest Declared | Declared when? | Type of Interest | Decisions Taken |
|---|--|----------------|---|-------------------------|
| Amanda Adler - Diabetologist | None declared | July 2012 | N/A | N/A |
| Christine Bundy (co-opted expert in mental health) | Holds a Scientific Advisory Board position with Simple Healthcare Products for which an honorarium is received for attending approximately three meetings per year. | July 2012 | Non-specific personal pecuniary interest | Declare and participate |
| Maria Cowell – Community Diabetes Nurse Specialist | None declared | August 2012 | N/A | N/A |
| Indranil Dasgupta (co-opted expert nephrologist) | Has been a member of an advisory board on a new phosphate binder for chronic kidney disease for Mitsubishi Pharma Indranil Dasgupta (co-opted expert nephrologist) | June 2013 | Non-specific personal pecuniary interest | Declare and participate |
| Indranil Dasgupta (co-opted expert nephrologist) | Indranil Dasgupta (co-opted expert nephrologist) | June 2013 | Non-specific, non-personal pecuniary interest | Declare and participate |
| David Edwards (co-opted expert GP with a specialist interest in sexual dysfunction) | Acts as a Chair and member on a number of advisory boards. Has organised, chaired and presented at local, national and international meetings on male and/ or female sexual problems and stress. Has written guidelines, been filmed, reviewed/ written articles for both lay and medical press. These activities have been reimbursed by organisations including pharmaceutical companies in the form of transport, accommodation and sometimes honoraria. Companies that travel, accommodation and honoraria have been received from are | July 2013 | Non-specific personal pecuniary interest | Declare and participate |

| | | | | |
|---|---|-----------|--|-------------------------|
| | Bayer, Eli Lilly, Schwabe and Takeda & Menarini, Pfizer, ProStrakan and Owen Mumford. | | | |
| David Edwards (co-opted expert GP with a specialist interest in sexual dysfunction) | President of the British Society for Sexual Medicine, Member of Men's Health Expert Policy Group which aims to educate those in power especially Government and key stake holders. Travel/occasional accommodation but not time is paid for by Bayer. | July 2013 | Non-specific personal pecuniary interest | Declare and participate |
| David Edwards (co-opted expert GP with a specialist interest in sexual dysfunction) | Clinical advisor to the Klinefelter's National Association. Member of an advisory board for prostate cancer management known as atypical small acinar proliferation (ASAP). | July 2013 | Non-specific personal pecuniary interest | Declare and participate |

| | | | | |
|---|---|----------------------|---|--------------------------------|
| <p>David Edwards (co-opted expert GP with a specialist interest in sexual dysfunction)</p> | <p>Participated as a medical researcher for studies undertaken by the Universities of Oxford and Southampton.</p> | <p>July 2013</p> | <p>Non-specific personal pecuniary interest</p> | <p>Declare and participate</p> |
| <p>David Edwards (co-opted expert GP with a specialist interest in sexual dysfunction)</p> | <p>Chief investigator in the UK for a study on low dose aspirin. The study is sponsored by Bayer.</p> | <p>July 2013</p> | <p>Non-specific personal pecuniary interest</p> | <p>Declare and participate</p> |
| <p>Andrew Farmer – GP with a special interest in diabetes (joined the GDG on 7/11/2013) -</p> | <p>None declared</p> | <p>November 2013</p> | <p>N/A</p> | <p>N/A</p> |

| | | | | |
|---|---|-------------|--------------------------------------|--|
| Anne Bentley – Primary Care Pharmacist | None declared | July 2012 | N/A | N/A |
| Natasha Jacques – Secondary Care Pharmacist | Participation in advisory board on Management of Diabetes in Renal Disease (sponsored by Boehringer Ingelheim) 17.01.12 | August 2012 | Specific personal pecuniary interest | Declare and participate as in line with NICE policy, it is greater than one year since the conflict occurred and the topics this may relate to are discussed |
| Natasha Jacques – Secondary Care Pharmacist | Speaker on ‘Adherence Issues in Diabetes’- event sponsored by MSD 25.04.12 | August 2012 | Specific personal pecuniary interest | Declare and participate as in line with NICE policy, it is greater than one year since the conflict occurred and the topics this may relate to are discussed |
| Yvonne Johns – patient/carer member | Has been asked by Diabetes UK Wales on behalf of the Welsh Medical Council to discuss and bring forward patient views on lixisenatide for the diabetes group in which she is involved. None of the patients have been asked to use the drug but were asked whether they would consider using it based in an information leaflet they received and their experiences of other GLP1’s | Sept 2013 | Personal non-pecuniary interest | Declare and participate |
| Ian Lewin - Diabetologist | None declared | April 2012 | N/A | N/A |
| Natasha Marsland – patient/carer member | Employed by Diabetes UK | Oct 2012 | Non-personal pecuniary interest | Declare and participate |
| Prunella Neale – Practice nurse | None declared | Oct 2012 | N/A | N/A |
| Jonathan Roddick - GP | Member of MSD advisory board for sitagliptin until appointment. | April 2012 | Specific personal | Able to participate as recommendations on |

| | | | | |
|--|---|--------------|--|---|
| | | | pecuniary interest(s) | drug treatment in type 2 diabetes were not made until 2014. |
| Mohamed Roshan – GP (August 2012 – October 2013) | Attended a diabetes advisory meeting. Reimbursement paid to the GP practice. | April 2012 | Specific non-personal pecuniary interest | Declare and participate |
| Mohamed Roshan – GP (August 2012 – October 2013) | Developer of Diabetes Education modules in Leicester which include modules on diabetes therapies between 2011 and 2013. No money was received. | October 2013 | Personal non-pecuniary interest | Declare and participate |
| Mohamed Roshan – GP (August 2012 – October 2013) | Developed and chaired meetings for GLP-1 educational program in Leicester for Primary Care as part of Department of Diabetes | October 2013 | Personal non-pecuniary interest | Declare and participate |
| Mohamed Roshan – GP (August 2012 – October 2013) | Attends advisory committee on Lixisenatide for Sanofi and will be trained in future as speaker (last attended March 2013). Received reimbursement to cover locum fees and staff time. | October 2013 | Specific personal pecuniary interest | Declare and withdraw |
| Mohamed Roshan – GP (August 2012 – October 2013) | Will attend conference for discussion on saxagliptin and cardiovascular outcomes evidence recently published. Reimbursement from Astra Zeneca | October 2013 | Specific personal pecuniary interest | Declare and withdraw |
| Mohamed Roshan – GP (August 2012 – October 2013) | Will be training as speaker for Bristol Myer Squibb | October 2013 | Specific personal pecuniary interest | Declare and withdraw |
| Mohamed Roshan – GP (August 2012 – October 2013) | Have chaired meeting for Insulin Degludec (Tresiba) in Sept 2013. Locum expenses reimbursed by Novo Nordisk. | October 2013 | Specific personal pecuniary interest | Declare and withdraw |

| | | | | |
|--------------------------------|--|--------------|---|---|
| Sailesh Sankar - Diabetologist | Attended the International Diabetes Federation in 4th December 2011, the travel and subsistence was supported by Boehringer Ingleheim with in the ABPI regulation guidelines. | July 2012 | Specific personal pecuniary interest(s) | Able to participate as recommendations on drug treatment in type 2 diabetes were not made until 2014. |
| Sailesh Sankar - Diabetologist | Chaired an evening meeting on the 12th of June 2012 for GP educational session supported by Novo nordisk. | July 2012 | Specific personal pecuniary interest(s) | Able to participate as recommendations on drug treatment in type 2 diabetes were not made until 2014. |
| Sailesh Sankar - Diabetologist | October 2011 - did an evening educational session for GP's supported by Boehringer Ingleheim. | July 2012 | Specific personal pecuniary interest(s) | Able to participate as recommendations on drug treatment in type 2 diabetes were not made until 2014. |
| Sailesh Sankar - Diabetologist | Principal Investigator for Roche EXPERT study. The study recruited patient to use an EXPERT bolus advisor blood glucose monitor versus a Nano monitor. This study was in relation to feasibility of use of bolus advisor in patients with Type 1 diabetes. In this study 9 | October 2012 | Non-personal specific pecuniary interest(s) | Declare and participate |

| | | | | |
|--------------------------------|--|-----------|--|-------------------------|
| | patients were recruited from Feb 2012 onwards and study was completed in October 2012. This study was funded by ROCHE to meet the expenses of the overheads and running of the study at UHCW site. The UHCW Trust has invoiced the company and the funding yet to be received. The exact amount can be confirmed on receipt. | | | |
| Sailesh Sankar - Diabetologist | Research nurse team was also involved in a retrospective data collection for study/audit conducted at UHCW trust in relation to use of INSULINX blood glucose monitoring in patients with Type 1 diabetes. Funding was (£150.00 per patient data collected) was agreed by the trust R and D in relation to this project. This study was funded by ABOTT diabetes care This was done over September to October 2012 period. Approximately 10 patient's data was collected for this study. | July 2013 | Specific non-personal pecuniary interest | Declare and participate |
| Sailesh Sankar - Diabetologist | Receiving a grant from Novo Nordisk to lead development of an education application for computer and phone devices for clinicians and medical students. The application will covering managing blood glucose levels for people with diabetes on insulin and preventing ketoacidosis. Novo Nordisk produce insulin licensed for us in people with type 1 and type 2 diabetes. | July 2013 | Specific non-personal pecuniary interest | Declare and participate |

A.2.2 Declarations of interest for 2009 (NICE clinical guideline 87)

| Name | Interest declared | Declared when? | Type of interest? | Decisions taken |
|----------------------|-------------------|----------------|-------------------|-----------------|
| Amanda Adler (Chair) | None | February 2008 | N/A | N/A |

| Name | Interest declared | Declared when? | Type of interest? | Decisions taken |
|------|--|----------------|-------------------|-----------------|
| | <p>The grant paid for economy class flights, accommodation and registration for the meeting. I was not required (and did not) attend any Takeda symposium or meeting at this venue and received no personal payment (flights, accommodation and meeting registration were arranged by Takeda within ABPI guidelines – I did not actually receive any money).</p> <p>15/11/08 “Novel approaches to hypertension” – I chaired a session at a meeting sponsored by Novartis.</p> <p>20/11/08 “eGFR and Diabetes in General Practice” – speaker at Shering Plough sponsored meeting.</p> <p>27/11/08 “Changes in the NHS and how they will affect diabetes care” – speaker at Eli Lilly sponsored meeting.</p> <p>15/01/08 “Current controversies in Diabetes Care” – speaker at MSD sponsored meeting</p> <p>24/1/08 “Preparing for the future – how to get a consultants post” – speaker at Manchester Respiratory SpR teaching (event was sponsored by GSK).</p> <p>11/3/08 “Aliskiren – Regional Advisory Board meeting” – attended Novartis Advisory Board.</p> <p>13/5/08 “Medicolegal aspects in Diabetes Care” – speaker at Takeda sponsored meeting.</p> <p>09/7/08 Debate “Should diabetes be managed exclusively in primary care” – speaker at Takeda sponsored meeting.</p> <p>23/7/08 “How not to get sued in Diabetes Care” – speaker at MSD sponsored meeting.</p> <p>12/08/08 “Update on local diabetic glycaemic guidelines” – speaker at Eli Lilly sponsored meeting.</p> <p>07/10/08 “New developments in Diabetes” – speaker at Eli Lilly sponsored meeting.</p> <p>06/11/08 “Individualising treatment in Diabetes” – speaker at Novartis sponsored meeting</p> <p>04/02/09 “GSK Round Table discussion on potential results of RECORD study” – attended GSK regional advisory board meeting</p> <p>My department has previously received research grants from GSK (more than 12 months ago) and Sanofi-Aventis</p> | | | |

| Name | Interest declared | Declared when? | Type of interest? | Decisions taken |
|---------------------|--|----------------|---------------------------------|---|
| Brown | <p>agents or equipment used in diabetes management for the following companies:</p> <p>Novo Nordisk, Glaxo Smith Kline, Takeda, Roche, Sanofi Aventis, Merck Sharp & Dohme, Pfizer.</p> <p>Spoken at educational meetings sponsored by some or all of the above companies.</p> <p>Advisory meetings 20/07/8</p> <p>19/4/07 Takeda</p> <p>27/6/07 Novo Nordisk (International Liaison meeting following American Diabetes Assn meeting)</p> <p>6/7/07 Glaxo SmithKline</p> <p>20/7/07 Novartis 'Round Table' clinicians discussion.</p> <p>9/8/07 Astra Zeneca</p> <p>19/10/07 Merck Sharp & Dohme.</p> <p>8/11/07 Glaxo SmithKline</p> <p>30/1/08 Roche Pharmaceuticals</p> <p>2/4/08 Sanofi Aventis. As a committee member of the Primary Care Diabetes Society, the Society has received sponsorship in the form of unrestricted educational grants from a variety of the pharmaceutical companies named above</p> | 2008 | pecuniary | |
| Tony Doherty | Presently working on a 2 year secondment with Diabetes UK as Service Advisor from my present Community Nurse Specialist post. Secondment commenced 15.01.08. | March 2008 | Personal non-pecuniary interest | Declare and participate |
| Julie Wood | None | March 2008 | N/A | N/A |
| Claudette Allerdyce | None | February 2008 | N/A | N/A |
| Yvonne Johns | None | February 2008 | N/A | N/A |
| Philip Ivory | None | March 2008 | N/A | N/A |
| Alistair McGuire | Advisory work for GSK but money received by working department | March 2008 | Non-personal pecuniary interest | Declare and participate |
| Tony Barnett | <p>Regularly advise Industry on new product development for diabetes including remuneration for such advice on Advisory Boards. Received remuneration for lectures at scientific meetings supported by Industry. Specifically, this includes companies involved in developing new products for diabetes including</p> <p>GlaxoSmithKline, Takeda, Eli Lilly, Novartis, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, Astra Zeneca and Bristol Myers Squibb.</p> | February 2008 | Personal pecuniary interest | Decision to appoint as a co-opted expert only due to personal pecuniary interests declared. |

| Name | Interest declared | Declared when? | Type of interest? | Decisions taken |
|---------------|--|----------------|---------------------------------|-----------------|
| | I have received competitive grants for research from the relevant companies mentioned below: GlaxoSmithKline, Takeda, Eli Lilly, Novartis, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, Astra Zeneca and Bristol Myers Squibb. | | Non-personal pecuniary interest | |
| Andrew Krentz | None | February 2008 | N/A | N/A |

A.3 Declarations of interest for 2006 (NICE clinical guideline 66)

Mrs Margaret C Bannister (Signed 22/06/2007)

Personal pecuniary interest:

- None

Personal family interest:

- Sister employed by Astra Zeneca as sales representative. As a member of their academy she had a weekend in Seville in June, to whom a partner was invited and I attended in this capacity.

Non-personal pecuniary interest:

- Any honorariums paid for lectures I deliver are paid directly to my employing PCT in the last 12 months I have been paid for such lectures by:
 - Takeda £150
 - GlaxoSmithKline £150

Personal non-pecuniary interest:

- None

Professor Melanie Davies (Signed 17/07/2007)

Personal pecuniary interest:

- Advisory Board for Eli Lilly (exenatide)
- Speaker fees for Sanofi-Aventis (insulin glargine)
- Advisory Board for Novo Nordisk (insulin detemir)
- Advisory Board for MSD for DPP IV and ezetimibe

Personal family interest:

- None

Non-personal pecuniary interest:

- Educational research grants from Servier/Pfizer and Novo Nordisk to support departmental research

Personal non-pecuniary interest:

- Principal investigator for the DESMOND RCT

Mrs Barbara Elster (Signed 18/07/2007)

Personal pecuniary interest:

- None

Personal family interest:

- None

Non-personal pecuniary interest:

- None

Personal non-pecuniary interest:

- None

Dr Roger Gadsby (Signed 17/07/2007)

Personal pecuniary interest:

- Member of Advisory Board for Novo Nordisk, Takeda, Pfizer, MSD and Merck Pharma.
- Speaker at educational events sponsored by Merck Pharma

Personal family interest:

- None

Non-personal pecuniary interest:

- I am Medical Advisor to Warwick Diabetes Care at Warwick Medical School, Warwick University, an organisation which provides diabetes educational programmes across the UK. Several of the courses are supported by unrestricted educational grants from pharma companies. In the past 12 months these have been from Novo Nordisk, Eli Lilly, GSK, Sanofi-Aventis and Lifescan.

I am Honorary Treasurer of the Primary Care Diabetes Society which has received educational grants from GSK, Takeda, Novo Nordisk, Eli Lilly, Sanofi-Aventis, Servier, Roche Diagnostics and Merck Pharma.

Personal non-pecuniary interest:

- None

Ms Irene Gummerson (Signed 20/06/07)

Personal pecuniary interest:

- None

Personal family interest:

- None

Non-personal pecuniary interest:

- None
- Personal non-pecuniary interest:
- None

Dr Martin Hadley-Brown (Signed 17/07/2007)

Personal pecuniary interest:

- Lecture and Advisory Board fees received from GSK, Takeda, Novartis, Novo Nordisk, Astra Zeneca. Only one of these (Novo Nordisk) exceeds £1,000 over the calendar year.

Personal family interest:

- None

Non-personal pecuniary interest:

- None

Personal non-pecuniary interest:

- None

Professor Philip D Home (Signed 21/07/2007)

Personal pecuniary interest:

- Shareholder (medical industries only): NONE Other earnings (private practice/other/legal reports) Total under £1,000 p.a.

Personal family interest:

- As a medical writer my wife occasionally has contracts with some of the companies named above.
- She has some funding from IDF and Novo Nordisk projects as above. She has no personal interest otherwise in any medical commercial organisation.
- I have no children under age 18 years.

Non-personal pecuniary interest:

- Continuing intermittent consultation (relates to diabetes/lipid technologies only) for external commercial healthcare organisations (on behalf of University of Newcastle upon Tyne):

Non-personal:

- Sanofi-Aventis, Paris/Guildford
- GlaxoSmithKline plc, Brentford
- Pfizer Inc, New York NY
- Merck Inc, Whitehouse Station NJ Merck-
- Sante, Paris
- Novo Nordisk A/S, Copenhagen / Crawley
- Novartis, Basel
- Recherche Groupe Servier, Paris Roche Diagnostics, Mannheim.

Other consultation for commercial organisations in last 12 months:

- UK and US financial, banking, conference, management consultancy, and support companies (when not knowingly commissioned by named pharmaceutical/diagnostic healthcare companies)
- Research/project grant support to hospital or university:
- Novo Nordisk A/S (discussions with Merck MSD UK, Pfizer UK) International Diabetes Federation:
- The IDF receives funding from all the above companies except Novartis but also Eli Lilly and Co, Takeda and Merck Sante for activities (Clinical Guidelines Task Force) in which I am involved but not remunerated for. If I change responsibilities at IDF this may extend to all concerns in the diabetes healthcare area.

Directorships:

- North East Diabetes Trust (charity) Diabetes Network International (charity)
- WorldWIDE Initiative for Diabetes Education (non-profit company)
- WorldWIDE is supported by GlaxoSmithKline, Merck Inc, Novartis, Pfizer and Sanofi-Aventis

Personal non-pecuniary interest:

- None

Mrs Emma Marcus (Form signed 25/06/2007)

Personal pecuniary interest:

- None

Personal family interest:

- None

Non-personal pecuniary interest:

- None

Personal non-pecuniary interest:

- None

Professor Jonathan Mant (Form signed 18/07/2007)

Personal pecuniary interest:

Consulting for:

- Expert-24 (Norwich Union website)
- PharmaSwiss (company that markets drugs in ex-Yugoslavia)

Personal family interest:

- Brother works for Quintiles (Biotech company)

Non-personal pecuniary interest:

- None

Personal non-pecuniary interest:

- Associate Director Schote Research Network

Mr John Roberts (Form signed 18/07/2007)

Personal pecuniary interest:

- None

Personal family interest:

- None

Non-personal pecuniary interest:

- None

Personal non-pecuniary interest:

- None

Dr Mark Savage

Personal pecuniary interest:

- Honoraria received for educational talks to GP/nurses from GSK, Takeda, Lilly, Novartis and Novo-Nordisk

Personal family interest:

- None

Non-personal pecuniary interest:

- None

Personal non-pecuniary interest:

- None

Dr Stuart Smellie (Form signed 18/07/2007)

Personal pecuniary interest:

- Occasional lecturing for Merck, Astra-Zeneca and MSD on lipid lowering and advisor in occasional advertising boards

Personal family interest:

- None

Non-personal pecuniary interest:

- None

Personal non-pecuniary interest:

- None

Dr Vora Jiten (Form signed 18/07/2007)

Personal pecuniary interest:

- As previously declared:
- Previous lecturing fees, honoraria for educational meetings from/for: GSK, Takeda, NovoNordisk, Lilly, Sanofi-Aventis, MSD, Novartis

Personal family interest:

- None

Non-personal pecuniary interest:

- None

Personal non-pecuniary interest:

- None